Video: Every Case Tells a Story| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • QA/QI
    • Technology
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Search results for: gout flare

Contemporary Prevalence of Gout & Hyperuricemia in the U.S.

Arthritis & Rheumatology  |  May 31, 2019

Using 2007–2016 data from NHANES, a nationally representative survey of American men and women, Chen-Xu et al. set out to estimate the current prevalence rates and decadal trends of gout and hyperuricemia in the U.S.

Filed under:ConditionsGout and Crystalline ArthritisResearch Rheum Tagged with:Arthritis & RheumatologyGouthyperuricemiaResearchurate-lowering therapies

Gout & Sexual Function

Lara C. Pullen, PhD  |  April 22, 2019

Pain, physical disability and joint deformity have been linked to sexual dysfunction. New research suggests gout may also significantly affect relationships and intimacy. The study found the physical effects of gout on intimacy, such as joint pain, were the top-ranked concern for gout patients…

Filed under:ConditionsGout and Crystalline Arthritis Tagged with:disabilityGoutintimacysex

Research Is Advancing Our Understanding of Gout & Hyperuricemia

Lara C. Pullen, PhD  |  March 19, 2019

CHICAGO—The Gout and Hyperuricemia scientific session at the 2018 ACR/ARHP Annual Meeting opened with a talk by Tony R. Merriman, PhD, a research professor at the University of Otago, New Zealand. His talk focused on molecular epidemiology, with an emphasis on the interactions between genes and environmental exposures, and their contributions to gout. Dr. Merriman…

Filed under:ConditionsGout and Crystalline ArthritisMeeting Reports Tagged with:2018 ACR/ARHP Annual MeetingGoutHuman Functional Genomics Projectshyperuricemia

New Study: Does Urate-Lowering Therapy Reduce Gout-Patient Mortality?

New Study: Does Urate-Lowering Therapy Reduce Gout-Patient Mortality?

Ruth Jessen Hickman, MD  |  March 18, 2019

Results of a recent study in Arthritis & Rheumatology fail to clarify whether urate-lowering therapies may potentially reduce mortality risk in patients with gout.1 The study also underscores the fact that many physicians are not following the ACR guideline to help their patients achieve target serum urate levels. Partly because of this, it remains unclear…

Filed under:ConditionsGout and Crystalline ArthritisResearch Rheum Tagged with:Allopurinolurate-lowering therapies

Coding Corner Question: Use Level 3 or 4 for RA/Gout Patient?

From the College  |  March 11, 2019

A 60-year-old man returns for a follow-up related to his diagnoses of rheumatoid arthritis and chronic gout of his right ankle and foot, without tophi. He reports the gout flares have subsided in his ankle. He takes 450 mg of allopurinol daily. He has rheumatoid factor-positive rheumatoid arthritis, which previously affected multiple sites, without organ…

Filed under:Billing/CodingConditionsFrom the CollegeGout and Crystalline ArthritisRheumatoid Arthritis Tagged with:Current Procedural Terminology (CPT) codesGout

Coding Corner Answer: Use Level 3 or 4 for RA/Gout Patient?

From the College  |  March 11, 2019

Take the challenge. CPT: 20611-LT, J7325-EJ ICD-10: M17.12, E66.01, Z68.41 CPT: 99213 ICD-10: M1a.0710, M05.79 History—The history of present illness was extended. The review of systems was extended, and two past family social history elements were documented. This makes the history level detailed. Examination—Five systems were examined. This makes the exam level detailed. Medical decision…

Filed under:Billing/CodingConditionsFrom the CollegeGout and Crystalline ArthritisRheumatoid Arthritis Tagged with:Current Procedural Terminology (CPT) codesGout

5 Takeaways from the ACR’s Gout Clinical Quality Measures

Carina Stanton  |  August 7, 2018

With electronic clinical quality measures tailored for treating gout patients, physicians and their teams now have tools to measure and improve gout care performance and outcomes…

Filed under:ConditionsGout and Crystalline Arthritis Tagged with:Goutpatient careQuality Measuresurate-lowering therapies

Gout Emergency Department Visits Up

Lara C. Pullen, PhD  |  July 16, 2018

In the past nine years, visits to the emergency department by gout patients have increased by almost 27%. Researchers suggest physicians may not adequately be addressing the burden of gout and the underlying accumulation of uric acid, driving the dramatic increase in emergency department visits in the U.S…

Filed under:ConditionsGout and Crystalline Arthritis

New Study Raises Cardiovascular Questions about Febuxostat for Gout

Lara C. Pullen, PhD  |  April 30, 2018

New research raises questions about the cardiovascular safety of febuxostat for gout patients compared with allopurinol. The study found that although febuxostat was noninferior to allopurinol, febuxostat-treated patients had similar overall rates of major adverse cardiovascular events as allopurinol-treated patients, but had higher rates of all-cause mortality and cardiovascular mortality…

Filed under:ConditionsGout and Crystalline Arthritis Tagged with:AllopurinolcardiovascularFebuxostathyperuricemiarisk

Study Finds Newer Gout Drug Poses Risk to Heart Patients

Gene Emery  |  March 12, 2018

(Reuters Health)—Gout sufferers with major pre-existing heart disease face a higher risk of death if they are treated with the drug febuxostat, a large long-term study has concluded. The risk of death from cardiovascular disease was 34% higher with febuxostat than with allopurinol. When researchers considered deaths from any cause, the risk was 22% higher…

Filed under:ConditionsGout and Crystalline Arthritis Tagged with:AllopurinolCardiovascular diseaseFebuxostatGoutHeart Diseasestroke

  • « Previous Page
  • 1
  • …
  • 4
  • 5
  • 6
  • 7
  • 8
  • …
  • 17
  • Next Page »
  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences